Haemate P

Haemate P is a powder for solution for injection that contains human coagulation factor VIII and human von Willebrand factor. It is supplied as a prescription‑only concentrate without a listed strength, intended for intravenous administration in the European market.

Haemate P is indicated for the management of bleeding disorders that involve deficiency of factor VIII and von Willebrand factor. It is used in clinical practice for: - Prophylaxis of bleeding episodes in hemophilia A - On‑demand treatment of acute bleeds in hemophilia A - Surgical support in patients with hemophilia A - Treatment of von Willebrand disease types 1, 2 and 3 - Management of combined factor VIII/VWF deficiency during bleeding crises

Side effects of Haemate P reflect the typical profile of plasma‑derived factor concentrates. They are reported in clinical use and post‑marketing surveillance.

Common: - Headache - Fever or chills - Nausea or vomiting - Injection site erythema or swelling - Mild arthralgia

Serious: - Allergic reactions including anaphylaxis - Development of inhibitors (neutralizing antibodies) to factor VIII or VWF - Thromboembolic events - Renal dysfunction in rare cases - Severe hypertension

When prescribing or administering Haemate P, clinicians should consider several safety aspects. Important precautions include: - Assessing patient history for inhibitors to factor VIII or VWF before use - Monitoring for signs of allergic reaction during and after infusion - Evaluating renal and hepatic function in patients with pre‑existing disease - Using caution in patients with a history of thrombosis or cardiovascular disease - Ensuring proper aseptic technique to prevent contamination - Adjusting dosage based on individual pharmacokinetic response when available

Haemate P may interact with other agents that affect hemostasis or immune response. Interaction considerations are:

Avoid: - Concurrent use of pro‑coagulant agents (e.g., activated prothrombin complex concentrates) without specialist guidance - High‑dose aspirin or other non‑steroidal anti‑inflammatory drugs that increase bleeding risk

Use with caution: - Antifibrinolytic drugs such as tranexamic acid (monitor for thrombotic signs) - Immunosuppressive therapies that may alter inhibitor development - Other plasma‑derived products (potential additive viral risk) - Vaccines administered shortly before or after infusion (monitor immune response)